Nasus Pharma
Powder-based Intra-nasal Products
Company Overview
Snapshot
Founded in May 2019 by Udi Gilboa and Dr. Dalia Meggido, Nasus Pharma operates with 1–10 employees. The company has raised a total of $25 million across two funding rounds. Nasus Pharma became public on NYSE in August 2025.
Business overview
Nasus Pharma is a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based intranasal products. The company's core technology utilizes microspheres to assist patients in acute emergency situations, such as opioid overdose and anaphylactic shock. Its portfolio includes intranasal naloxone (NS-001), intranasal epinephrine (NS-002), and Taffix, serving the Health Tech & Life Sciences sector, specifically in.
Strategic signal
In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002 Intranasal Epinephrine Powder, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen® with accelerated speed to therapeutic threshold. This signals strong clinical validation for its lead product candidate, indicating potential for a disruptive treatment in anaphylaxis and a positive trajectory for investors in the biopharmaceutical market.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent clinical development for Nasus Pharma?
- In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002 Intranasal Epinephrine Powder, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen®.
- When did Nasus Pharma go public?
- Nasus Pharma became public on the NYSE in August 2025, completing its Initial Public Offering.
- What was a key financial event for Nasus Pharma in early 2026?
- In February 2026, Nasus Pharma announced the closing of a $15.0 million private placement.
- What is the status of Nasus Pharma's NS002 Intranasal Epinephrine program?
- In November 2025, Nasus Pharma announced the initiation of a Phase 2 clinical study for NS002 Intranasal Epinephrine Powder, with the first participant dosed. This followed approval from Health Canada to initiate the study.
- Has Nasus Pharma recently strengthened its leadership team?
- In November 2025, Nasus Pharma strengthened its leadership team by appointing Eyal Rubin as Executive Vice President and Chief Financial Officer.